论文部分内容阅读
目的:探讨五苓散加减联合小剂量奥曲肽治疗肝硬化难治性腹水的临床疗效。方法:选取肝硬化顽固性腹水患者45例,随机分为对照组22例和治疗组23例。对照组给予奥曲肽0.1mg皮下注射,治疗组在对照组治疗基础上结合五苓散加减治疗。比较两组治疗效果。结果:经过15天治疗,治疗组总有效率为91.3%,对照组为77.2%,治疗组总有效率优于对照组(P<0.05)。结论:五苓散加减联合小剂量奥曲肽治疗肝硬化难治性腹水疗效确切,值得临床推广应用。
Objective: To investigate the curative effect of Wu Ling San combined with low-dose octreotide in treatment of refractory cirrhosis and ascites. Methods: Forty-five patients with cirrhosis and refractory ascites were randomly divided into control group (22 cases) and treatment group (23 cases). Control group given octreotide 0.1mg subcutaneous injection, the treatment group in the control group based on the combination of Wulingsan plus treatment. Compare the treatment effect of two groups. Results: After 15 days of treatment, the total effective rate was 91.3% in the treatment group and 77.2% in the control group. The total effective rate in the treatment group was better than that in the control group (P <0.05). Conclusion: Wu Ling San combined with low-dose octreotide treatment of cirrhosis refractory ascites definite effect, worthy of clinical application.